| Name | Azithromycin hydrate |
| Description | Azithromycin hydrate (CP-62993 dihydrate) is a semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. |
| Cell Research | THP-1 cells (106 cells in 1 mL RPMI medium, without antibiotics, growth factors or serum) are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μL of the test compound is added followed by 50 μL of LPS (final concentration of 10 μg/mL). After 24h (37°C and 5% CO2) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm with background subtraction at 630 nm. |
| In vivo | Azithromycin (50 mg/kg) does not alter bronchoalveolar lavage inflammatory parameters or LDH levels in a mouse asthma exacerbation model. It also does not induce general inflammation or LDH release, but enhances interferon-stimulated gene expression and MDA5, a pattern recognition receptor, effectively lowering viral load without affecting RIG-I in exacerbating mice[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 10 mg/mL (12.74 mM), Sonication is recommended.
DMSO : 50 mg/mL (63.69 mM), Sonication is recommended.
Ethanol : 93 mg/mL (118.47 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | CP-62993 Dihydrate | CP62993 Dihydrate | CP-62993 | CP62993 | CP 62993 Dihydrate | CP 62993 | Bacterial | Azithromycin hydrate | Azithromycin Dihydrate | Azithromycin | Autophagy | Antibiotic | 50S ribosome | 23S rRNA |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Hemin | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Fenpyroximate | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Anti-Parasitic Compound Library | Bioactive Compound Library | Autophagy Compound Library | Anti-Cancer Clinical Compound Library | Saccharide and Glycoside Natural Product Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
